524 related articles for article (PubMed ID: 31965967)
21. Biomarkers of chronic spontaneous urticaria and their clinical implications.
Asero R; Cugno M
Expert Rev Clin Immunol; 2021 Mar; 17(3):247-254. PubMed ID: 33496195
[No Abstract] [Full Text] [Related]
22. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
23. IgE FcɛR1β polymorphism and risk of developing chronic spontaneous urticaria: A study in an ethnic Kashmiri population.
Rasool R; Shera IA; Nissar S; Yousuf Q; Shah ZA
Allergol Immunopathol (Madr); 2015; 43(3):243-8. PubMed ID: 24953255
[TBL] [Abstract][Full Text] [Related]
24. Lower IgA Levels in Chronic Spontaneous Urticaria Are Associated With Lower IgE Levels and Autoimmunity.
Sauer M; Scheffel J; Frischbutter S; Kolkhir P; Xiang YK; Siebenhaar F; Altrichter S; Maurer M; Metz M; Krause K
Front Immunol; 2021; 12():657211. PubMed ID: 34012441
[TBL] [Abstract][Full Text] [Related]
25. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria.
Kulumbegov B; Chikovani T; Gotua M; Kikodze N; Magen E
Allergy Asthma Proc; 2023 Nov; 44(6):429-435. PubMed ID: 37919851
[No Abstract] [Full Text] [Related]
27. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
[TBL] [Abstract][Full Text] [Related]
28. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria.
Acer E; Kaya Erdogan H; Yüksel Çanakçı N; Saracoglu ZN
Cutan Ocul Toxicol; 2019 Mar; 38(1):5-8. PubMed ID: 29969297
[TBL] [Abstract][Full Text] [Related]
29. Omalizumab may not inhibit mast cell and basophil activation in vitro.
Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
[TBL] [Abstract][Full Text] [Related]
30. Thyroid Autoimmunity and Autoimmunity in Chronic Spontaneous Urticaria Linked to Disease Severity, Therapeutic Response, and Time to Remission in Patients with Chronic Spontaneous Urticaria.
Chanprapaph K; Iamsumang W; Wattanakrai P; Vachiramon V
Biomed Res Int; 2018; 2018():9856843. PubMed ID: 30515422
[TBL] [Abstract][Full Text] [Related]
31. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
MacGlashan D; Saini S; Schroeder JT
J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
[TBL] [Abstract][Full Text] [Related]
32. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria.
Asero R; Marzano AV; Ferrucci S; Lorini M; Carbonelli V; Cugno M
Clin Exp Immunol; 2020 Jun; 200(3):242-249. PubMed ID: 32115683
[TBL] [Abstract][Full Text] [Related]
33. Predictors of treatment response in chronic spontaneous urticaria.
Fok JS; Kolkhir P; Church MK; Maurer M
Allergy; 2021 Oct; 76(10):2965-2981. PubMed ID: 33539587
[TBL] [Abstract][Full Text] [Related]
34. Treatment of chronic autoimmune urticaria with omalizumab.
Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
[TBL] [Abstract][Full Text] [Related]
35. Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
Asero R; Ferrucci SM; Calzari P; Consonni D; Cugno M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108654
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
Gimenez-Arnau AM; Salman A; Podder I
Eur J Dermatol; 2024 Feb; 34(1):3-12. PubMed ID: 38557452
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience of a chronic urticaria referral university center.
Andrade Coelho Dias G; Cunha Coelho F; Filippo P; Lacerda Pedrazzi D; Nogueira Arraes AC; Perelló MI; Chigres Kuschnir F; Costa E
Eur Ann Allergy Clin Immunol; 2020 May; 52(3):112-120. PubMed ID: 31287262
[No Abstract] [Full Text] [Related]
38. Clinical experience of a specialized urticaria outpatient clinic from a Portuguese UCARE.
Esteves Caldeira L; Paulino M; Coutinho C; Neto M; Pereira Barbosa M; Costa C
Eur Ann Allergy Clin Immunol; 2023 Jan; 55(1):9-18. PubMed ID: 33949172
[No Abstract] [Full Text] [Related]
39. The Role of antiFcεRIα Autoantibodies Detection and Autologous Serum Skin Test in Comparison To Histamine Release Assay in Diagnosis of Chronic Autoimmune Urticaria.
ELBadawy NE; Gharib K
Egypt J Immunol; 2020 Jan; 27(1):141-155. PubMed ID: 33180396
[TBL] [Abstract][Full Text] [Related]
40. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
